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Abstract
For many years, microbial adjuncts have been used to supplement the diets of farm animals and humans. They have evolved since the 1990s to
become known as probiotics, i.e. functional food with health beneﬁts. After the discovery of a possible link between manipulation of gut
microﬂora in mice and obesity, a focus on the use of these beneﬁcial microbes that act on gut microﬂora in animal farming was undertaken and
compared with the use of probiotics for food. Beneﬁcial microbes added to feed are classiﬁed at a regulatory level as zootechnical additives, in
the category of gut ﬂora stabilizers for healthy animals and are regulated up to strain level in Europe. Intended effects are improvement of
performance characteristics, which are strain dependent and growth enhancement is not a prerequisite. In fact, increase of body weight is not
commonly reported and its frequency is around 25% of the published data examined here. However, when a Body Weight Gain (BWG) was
found in the literature, it was generally moderate (lower than or close to 10%) and this over a reduced period of their short industrial life.When
it was higher than 10%, it could be explained as an indirect consequence of the alleviation of the weight losses linked to stressful intensive
rearing conditions or health deﬁciency. However, regulations on feed do not consider the health effects because animals are supposed to be
healthy, so there is no requirement for reporting healthy effects in the standard European dossier. The regulations governing the addition of
beneﬁcial microorganisms to food are less stringent than for feed and no dossier is required if a species has a Qualiﬁed Presumption of Safety
status. The microbial strain marketed is not submitted to any regulation and its properties (including BWG) do not need to be studied. Only
claims for functional or healthy properties are regulated and again growth effect is not included. However, recent studies on probiotic effects
showed that BWG could also be observed in humans, or not, according to species and strains. Determining the signiﬁcance of farm animal
results for extrapolation to humans, especially regarding body weight improvement, was not easy because they do not use the same microbial
strains nor always the same species. Furthermore, the framework for the management of microbials added to feed or to food differ, especially
with regard to goal, timescale and lifestyle. So no one can exclude the possibility that beneﬁcial microorganisms having probiotic effects may
have long-term effects in humans that cannot be seen to date in animals, where short-term use is the rule. A possible link to obesity cannot be
excluded in relation to timescale, species and strain speciﬁcity. To conclude, beneﬁcial microorganisms added in feed are key factors stringently
regulated for short-term improvement of zootechnical performances in animals and their use does not entirely parallel that of human
probiotics. So extrapolation of farm animal results to humans is biased and not sufﬁcient to be conclusive regarding the existence or not of a link
between probiotics and obesity. From a toxicological and nutritional point of view and considering recent ﬁndings on a link between antibiotic
use in early life and excessive risk of becoming overweight, one suggestion is to study the at-risk population in Europe, pregnant women and
their babies before and after birth and during early childhood, in an epidemiological long-term cohort survey.
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Presentation and Comparison of Probiotics
use in the Feed/food Chain
Probiotics are deﬁned as ‘Live microorganisms which when
administered in adequate amounts confer a health beneﬁt on
the host’ [1]. They cover a wide range of living microorganisms
with supposed positive effects on gut ﬂora and producing a
large number of substances (deﬁned or not) supporting many
different effects which are, for the time being, far from proven.
For example, many speciﬁc health claims proposed by
industrial partners for food probiotics failed recently to be
validated by the European Food Safety Agency commission
because of insufﬁcient scientiﬁc or clinical evidence [2]. To
date, probiotics are classiﬁed in the category of functional
products [3] and considered to be beneﬁcial microorganisms
[4]. However, regulatory texts do not mention the word
probiotic anywhere, and refer to beneﬁcial microorganisms
without any other details. This situation differs from that of
antibiotics, which also act on gut microbiota and are used in
animal husbandry. Antibiotics are stable chemical substances,
have a well-deﬁned speciﬁcity, and were recognized and named
as growth promoters in regulatory texts until the publication
of the regulation (EC) 1831/2003 [5] in which they were
banned.
Beneﬁcial microbes are feed additives in Europe [6] and are
called Direct Fed Microbials in other world regions. In animal
husbandry, they were initially used, in the twentieth century,
to reduce intestinal colonization by Salmonella in chickens, to
increase the feed utilization efﬁciency and reduce diarrhoea in
pigs, and to increase milk production and decrease diarrhoea
in cattle. Their beneﬁcial effects were complementary with
those of the antibiotics used simultaneously as growth
promoters at low doses in animal diets [7]. This growth
promoter effect observed with antibiotics was supposed to be
related to gut health stabilization [7] and it was a proof that
manipulation of animals’ microﬂora through diet was efﬁcient
in enhancing animals’ productivity. So when antibiotics were
banned from the feed market in 2006 [8], interest in beneﬁcial
microbes having potentially similar effects increased and their
regulation was updated in 2003 [5,9].
In human food, beneﬁcial microorganisms are mainly
present in fermented items [10] or as ingredients or process-
ing aids and are known to have a long history of use, especially
through the use of fermented milk products [6]. The use of
probiotics as ingredients or functional foods conferring a
health beneﬁt has gained scientiﬁc attention since the 1980s,
ﬁrst in Japan then in Europe, and it has mushroomed since
2000 [4]. However, a recent suggestion hypothesized that a
widespread and haphazard ingestion of microorganisms may
promote obesity in humans by altering the intestinal ﬂora
balance [11,12]. This remains controversial and probiotic
specialists reacted quickly to this bombshell [13,14], especially
the well-known and recognized International Scientiﬁc Asso-
ciation of Probiotics and Prebiotics, which was founded in
2000 [15]. However, the discovery of a link between the
manipulation of gut microﬂora and obesity, as demonstrated in
mice for certain bacterial species [16], lends credibility to this
hypothesis [17]. In the present themed review, we underline
some important differences between microbial feed additives
and probiotics for food, taking into account species and strains
requirements resulting from the regulations in force and the
main literature dealing with effects in farm animals or humans,
especially body weight gain and health properties. An evalu-
ation of the signiﬁcance of extrapolation of data from animal
studies to humans is presented.
Comparison of Species and Strains
Requirements in Feed/food
Both bacteria and yeast are used as microbial feed additives.
Around 20 microbial feed additives are authorized in the
European Union [9]. Depending on the animal species,
ruminant, pig or poultry, speciﬁc microorganisms are pre-
ferred, i.e. yeast (especially Saccharomyces cerevisiae) plays a
major role in ruminants, whereas Bacillus spp., Enterococcus spp.
and Lactobacillus spp. are more likely to be efﬁcient in pigs and
poultry [18,19]. Different strains belonging to similar species
have different properties and so effects/beneﬁts can be
different from one strain to another within the same species
[20].
According to regulation 1831/2003/EC [5], in force at the
time of writing, microorganisms are authorized as ‘zootech-
nical additives’ for feed. A zootechnical additive is ‘any additive
used to affect favourably the performance of animals in good
health or used to affect favourably the environment’. This
group includes, among others, gut ﬂora stabilizers, a category
that includes microorganisms. Applications for approval must
follow guidelines to establish a relevant dossier [21]. Approval
is granted for a strain or a mix for which molecular
characterization and identiﬁcation at species and strain levels
are needed. Zootechnical performance for at least one
characteristic must be demonstrated to obtain an authoriza-
tion for a target animal species only and more speciﬁcally for a
category of age for this species (i.e. weaning piglets, post-
weaning piglets, fattening pigs and sows) but growth enhance-
ment is not a prerequisite (the category ‘Growth Enhancers’
was deleted in EEC regulation 1831/2003 [5]). In fact these
additives ‘must affect favourably animal production,
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performance or welfare by affecting the gastrointestinal ﬂora
or digestibility of feedingstuffs’ as cited in the article 5(3) of
regulation 1831/2003/EC [5]. Performance characteristics
include feed efﬁciency through improvement of feed conver-
sion ratio, average daily weight gain through improvement of
body weight gain (BWG), milk or egg production, carcass
composition or herd performance [22]. A scientiﬁc dossier for
the approval process is needed for each marketed product.
To put microorganisms on the feed market or to improve
their efﬁciency, much of the current research focuses on the
choice and the properties of a suitable strain. It is important
(but not required for the European dossier) to understand the
mode of action of probiotics in the gut. This makes it possible
to achieve a better level of control and to deﬁne appropriate
dosages for a speciﬁc target. For the choice of strains, basic in
vitro prerequisite criteria, related to identiﬁcation, enumera-
tion [23,24], safety, gut survival and colonization ability, as well
as other criteria related to technological process and probi-
osis, are necessary [25]. It is worth mentioning that in general
only a few strains have the right basic proﬁle [26] and only 1&
become a marketable strain. This improves the accumulation
of knowledge and reinforces the quality and traceability of
those beneﬁcial microbes and the supposed reproducibility of
a given effect at a strain level along with appropriate dose
administration. However, in spite of all of these accurate
precautions of selection, the results of probiotic supplemen-
tation are still dependent on numerous known and unknown
parameters: doses, compatibility with other additives present
in the diet, type of feeding, technology used to formulate the
diet (pelleting or not), type of animal target, quality of hygiene
in the herd and environment [27].
Regulations governing the addition of beneﬁcial microor-
ganisms with probiotic effects to food are less stringent than
for feed; the simple fact of belonging to a species with a
known safe history of use with a Qualiﬁed Presumption of
Safety status is enough and no dossier is required. Further-
more, there is no regulation at the strain level for human
probiotics used as ingredients. Within a species with Qualiﬁed
Presumption of Safety status, many different strains can be
used whatever their phenotypic and genotypic speciﬁcities
although important genomic intraspecies variations have been
identiﬁed, for example for lactobacilli (Lactobacillus acidophilus
[28], Lactobacillus casei [29], Lactobacillus plantarum [30],
Lactobacillus salivarius [31]). Those genomic strain-speciﬁc
diversities can provide important phenotypic differences
associated with a range of effects from adverse [32] to
positive [20]. These intra-species speciﬁcities are illustrated by
the following examples: adhesion and mucus-binding proper-
ties in Lactobacillus reuteri strains [33]; mechanisms of protec-
tion of transepithelial barrier function in L. salivarius strains
(bacteriocin and hydrogen peroxide production) [34]; and
enzymatic production such as that of a-glucosidase activity in
lactic acid bacteria, a trait considered negative for diabetic and
obese humans [35]. So knowledge of strain-speciﬁc properties
is lacking in food use and this is the main critical point for a
targeted use. This explains recent failures in validation of the
speciﬁc health claims proposed by industrial partners for these
food probiotics by the European Food Safety Agency
commission because of insufﬁcient scientiﬁc or clinical
evidence [2,20].
Comparison of Occurrence of BWG in
Animals and Humans
As a result of the increase in livestock production, modern
methods of massive livestock rearing (i.e. intensive industrial
production) have generated many animal stresses, especially
density stress. As a result, digestive diseases have increased
and animal performances have been negatively affected [18].
Microbial adjuncts were used as diet supplements to counter-
act those performance losses. Simon et al. [36] who compiled
data from the literature published between 1973 and 2000,
found that BWG and feed conversion ratio improvements
were rare for this period of time with such supplements.
Efﬁciency of these microbial adjuncts can also be deduced from
the review of Bernardeau et al. [4]: from 46 published animal
trials where Lactobacillus strains were used, only ten trials
showed a signiﬁcant BWG. In another review [6] where
different species and strains of probiotics were tested in
different animal trials, eight of the 33 referenced trials
presented a signiﬁcant BWG. Other data gave similar results
[37]. So increase of body weight is not commonly reported
and its frequency is around 25% of published data examined
here. However, when BWG was found in the literature
(Table 1) it was generally lower than or close to 10% (Table 1)
as previously reported [38,39]. Recently [40], BWG was
shown to be species dependent and some species had
negligible effects on weight or reduced it; however, some
species can improve weight gain by >10%, especially Lactoba-
cillus ingluviei in chickens and ducks [41], and by >20% in ﬁsh or
shrimp (Table 1) over a reduced period of their short
industrial lifespan as deﬁned in the regulatory guidelines [42].
This BWG is mainly a protein anabolism inducing lean meat
formation rather than a fatty weight gain [14] and is
consequently compliant with consumer and public policy
objectives. For example, it has been demonstrated that
beneﬁcial microbes fed to weaner and grower–ﬁnisher pigs
provide signiﬁcantly higher proportions of carcasses classiﬁed
in the top two categories of the SEUROP scale (S, superior,
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and E, excellent: lean meat >55%) giving an additional beneﬁt to
the farmer [43]. The mode of action of beneﬁcial microbes is still
hypothetical (Table 1) and has been reviewed in animals [44].
Human probiotics that promote health beneﬁts have received
a boost through increasing consumer demand for such products
[45]. As a consequence, there has been extensive research,
opening up doors for the use of probiotics and in various areas
[46]. Million et al. [40] were the ﬁrst to identify growth effects of
lactobacilli in humans, including infants <2 years old, lean adults
and overweight/obese adults, and highlighted that moderate
BWG in humans is Lactobacillus species-dependent.
Health Effects and Relation to Weight Gain
in Animals and Humans
Several studies (Table 1) have highlighted the health value of
lactobacilli in pigs, poultry, cattle, ﬁsh and other animals [4].
TABLE 1. Recent examples of beneﬁcial microbes used in animal husbandry and having growth promotion effects
Animal target Strains Inclusion dose
Signiﬁcant
improvement of
growth parameters
compared with
negative control
Hypothetical mode of action
proposed by authors [reference]
Poultry production
Broilers Processed at Low/high
drying temperature
Lactobacillus acidophilus KNU 31
Bacillus subtilis KNU 42
Saccharomyces cerevisiae KNU 55
Aspergillus oryzae KNU 48
LT/HT
4.0 9 108/1.0 9 102
4.8 9 109/2.0 9 104
1.0 9 104/1.2 9 102
4.3 9 107/1.0 9 103
BWG at day 42
LT/HT
+9.0%/ +7.5%
Higher gains and better feed
conversion ratios may be due to the
greater crude protein retention [64]
Broilers Clostridium butyricum 3 9 107 CFU C. butyricum/kg of diet +3.7% BWG at day 42 [65]
Broilers B. subtilis LS 1–2 0.45% in diet +8.35% BWG at day 35 Greater nutrient retention and
improvement of gut health [66]
Broilers L. acidophilus
B. subtilis
S. cerevisiae
107 CFU multi-microbe probiotic/kg of diet,
108 CFU multi-microbe probiotic/kg of diet,
109 CFU multi-microbe probiotic/kg of diet
+4.87% BWG at day 35
+8.28% BWG at day 35
+8.53% BWG at day 35
Greater apparent digestibility of
nutrients and improvement of gut
health [67]
Broilers Lactobacillus ingluviei CIP 102980 4 9 1010 Lactobacillus spp. per
animal inoculated: once,
or twice
+10.2% BWG
+13.5% BWG
[41]
Ducks L. ingluviei CIP 102980 4 9 1010 Lactobacillus spp. per animal
inoculated:
once,
or twice
+7.7% BWG
+14% BWG
[41]
Pig production
Pigs Propionibacterium freudenreichii
ssp. shermanii CIRM-BIA129
Pigs gavaged daily with
2 9 1010 CFU of P.
freudenreichii CIRM-BIA129
for 2 weeks
+10% BWG at day 14 Production of vitamins, modulation of
the intestinal microbiota or
anti-inﬂammatory properties [68]
Growing-ﬁnishing
pigs
Two strains of Bacillus
licheniformis
and one strain of B. subtilis
1.47 9 108 CFU of Bacillus
per g of supplement added
at 0.05% in diet
G:F increased in ﬁnisher
phase and in the overall
growing-ﬁnishing period.
Production of extracellular degrading
enzymes, better nutrient digestion
and utilization of feed; modulation
of immunity [69]
Ruminant production
Preweaning calves B. subtilis natto Daily dose of 1 9 1010 CFU of B.
subtilis natto
FE—15.5%
ADG + 12.9%
Advance the weaning age
of the calves—7.3 days
[70]
Male buffalo calves
Bubalus bubalis
L. acidophilus
S. cerevisiae
L. acidophilus and S. cerevisiae
at the dose of 1 9 109 and
3 9 109 and CFU/ﬂask/kg
FBW + 4% Beneﬁcial inﬂuence on rumen
fermentation [71]
Aquaculture
Fish
Epinephelus coioides.
S. cerevisiae P13 103, 105 and 107 CFU kg/diet Variations compared with
control groups:
PWG (103): +6.66%
PWG (105): +19.9%
PWG (107): +27%
Colonize the intestines, improve FE
and growth rate, induce
upregulation of innate cellular
and humoral immune
responses, increase the
resistance to challenge by
Streptococcus sp. and iridovirus [72]
Fish
Oreochromis niloticus
Rhodopseudomonas palustris
G06
Added to water at ﬁnal concentration
of 1 9 107 CFU/mL every 2 days
Higher ﬁnal weight,
BWG +23.37% at day 40
DWG + 22.64%
SGR + 12.28%
Enhance immune and health status,
thereby improving growth
performance [73]
Shrimp
Litopenaeus vannamei
B. subtilis strains, L10 and G1 Two different doses 105 and 108
CFU/g feed until the end of the
experiment (8 weeks)
Dose 105 CFU/g feed
FW: +36.14%
BWG: +45.60%
Dose 108 CFU/g feed
FW: +38.95%
BWG: +53.29%
Competitive exclusion, creation of a
hostile environment for pathogen
colonization; reduction of Vibrio spp.
populations in the gastrointestinal
tract; induction of digestive enzymes
stimulate the natural digestive
enzyme activity of the host; improve
appetite [74]
Growth parameter abbreviations: ADG, average daily gain; BWG, body weight gain; DWG, daily weight gain; F, feed; FE, feed efﬁciency; FBW, ﬁnal body weight; G, gain; LT/HT,
low drying temperature/high drying temperature; PWG, percentage of weight gain = [100 9 (ﬁnal body weight  initial body weight) (initial body weight)1]; SGR, speciﬁc
growth rate.
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Those beneﬁts may be a result of the active metabolites
synthesized by probiotic microorganisms, such as organic
acids, hydrogen peroxide, bacteriocins or bacteriocin-like
substances and cell-wall components, and imply their com-
mon adjuvant properties in relation to immunity [47].
Probiotic supplementation is recommended for the treat-
ment or prevention of a range of stress conditions and
diseases in a number of species submitted to intensive
rearing and promiscuity [18]. In fact, growth enhancement
effects are more likely in situations involving a stress of
some kind, as found on real farms rather than in university-
based trials, assuming that health effects and zootechnical
effects are closely related [4]. In animals, ingestion of a
supplemented diet containing selected microorganisms pre-
sented as probiotics makes it possible to counteract some of
the negative effects of stress [48,49] and leads to a
compensatory BWG. For example, in mice it was reported
that with a conventional diet, there were no signiﬁcant
differences between the mice receiving and those not
receiving the probiotic supplementation, in contrast to mice
fed a sub-optimal diet (i.e. having a nutritional stress) for
which BWG was around 30% with probiotic supplementa-
tion, although the nutritional value of these microorganisms
alone is negligible [50].
The use of live bacterial cultures in the animal industry,
whether to improve resistance to speciﬁc pathogens or to
non-speciﬁcally enhance animal health, improves production
parameters [51]. This health approach, although not taken into
consideration in regulation (which targets ‘animals already in
good health’, as indicated above), is reminiscent of that
described for food probiotics for which functionality is
associated with health beneﬁts. So, modiﬁcation of feed
additive regulation to include health effects (as Welfare
additives or Product quality additives) was proposed by the
FEEDAP Panel [52] at the European level, but this approach
has not been successful to date and some hurdles were
recently identiﬁed regarding use of probiotics in feed/food [2].
In fact, regulations on feed do not consider health effects, even
if supported by consistent scientiﬁc knowledge proving health
beneﬁts (which implicitly justify their use), because animals are
supposed to be healthy, so such regulations are not required for a
European dossier.
In food, the microbial strain used is not submitted to any
regulation and so its properties (including BWG) do not need
to be studied. However, as intended uses are for functional or
healthy properties only probiotic claims are recognized and
regulated [53] and again effect on body weight is not included.
In humans, recent papers have discussed the limits of current
studies related to the signiﬁcance of the link between
probiotics and weight gain or obesity [54–56].
Signiﬁcance of Animal Results for
Extrapolation to Humans
To assess the signiﬁcance of animal results for extrapolation to
humans we chose to see if there were any data where the same
probiotic strain was used in both animals and humans. To our
knowledge, no beneﬁcial microbes commercialized for feed/food
use in Europe or other world regions have been simultaneously
used both in animal husbandry and in humans, probably because
of the risk of confusing the marketed image. We therefore
focused on published data related to research (Table 2). Effects
concern mainly gut stabilization and immunity, and with a few
exceptions they are not identical for animals or humans, as
reported in the corresponding data (Table 2). Extrapolation of
farm animal results to humans is therefore biased and not
sufﬁcient to make a conclusive argument for the existence or
not of a link between probiotics and obesity because we do not
have any sustained history of use, nor any data regarding the
same strain applied both to animals and humans.
To ﬁnd an explanation for the aforementioned differences,
we addressed framework characteristics between microbials
for feed and probiotics for food because they differ greatly,
especially with regard to their conditions of use and their goals
(Table 3). In the timescale, long-term effects are also expected
from food probiotics, whereas feed microbial additives, to be
economically useful, must produce a quick response. For
example, typical industrial lifespans are 42–80 days for a
broiler chicken, around 120–200 days for shrimps, 6 months
for pigs, 18–24 months for ﬁsh, a few months for calves and a
few years for beef cattle. This duration is <5% of the entire life
expectancies of the corresponding animal species, which are
generally >10 years except for ﬁsh and shrimp (5–7 years). As
regards speciﬁc use in humans, safety assessment should
integrate long-term effects and consider possible chronic
effects, which were not deducible in humans on the basis of
this short-term use in animals. The stress effects linked to
lifestyle could also have a different incidence in humans, when
compared with animals because rearing in animals is exclusively
density dependent (intensive breeding) in contrast to humans
evolving in a less constrained environment.
Discussion and Conclusion
The main points identiﬁed here concerning the action of
beneﬁcial microorganisms added to feed/food on farm animals
and humans are (i) regulations for species and strain require-
ments is not parallel in feed/food; (ii) BWG is moderate in
animals and humans and not frequent; (iii) health effects in
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animals and humans were observed and could explained the
compensatory BWG; (iv) signiﬁcance of results in animals is
biased and not realistic for extrapolation to humans because of
different framework characteristics especially goal, timescale,
lifestyle and species and strain speciﬁcities.
Data on farm animals are not sufﬁcient for the purpose of
developing a conclusive argument for or against the existence
of a link between probiotics and obesity and no one can
exclude the possibility that beneﬁcial microorganisms with
probiotic effects may have long-term effects in humans that
cannot be seen in animals, where short-term use is the rule.
The development of food probiotics occurred at the end of
the second millennium and the epidemic of obesity in Europe
has been on the increase since the beginning of the third
millennium [57] so there is a need for research to discover
whether a link exists. A better way to investigate this question
would be to work directly on human cohorts. From a
toxicological and nutritional point of view, and considering
recent ﬁndings on antibiotic use in early life and an associated
and inadmissibly high risk of becoming overweight [58], the at-
risk population to be taken into consideration should be
pregnant women and their babies before and after birth and
during childhood. Zwiauer [59] reported that there are limited
data from well-designed controlled studies on the growth of
infants fed formulas supplemented with probiotics. The study
also pointed out that these widely used formulas presented no
indication of negative inﬂuence on infant growth in accordance
with previous studies, which also reported a growth effect
TABLE 2. Effects of identical beneﬁcial strains studied for potential use in animal production and for human consumption
(adapted from Bernardeau and Vernoux, [6] and updated)
Strains Human applications Animal applications
Bacillus cereus ATCC
14893 = IP 5832
Bactisubtil: probiotic medication used since 1955 under taxonomic
label Bacillus subtilis IP 5832 to treat diarrhoea, but is in fact Bacillus
cereus ATCC 14893, used in the 20th century as a feed additive
under the commercial name ‘Paciﬂor’ (Prodeta, Vannes, France) [75]
Paciﬂor: strain widely used before 2003 as feed additive in
animal nutrition (PaciﬂorTM; Prodeta) [75]
Sow and litter: administration beneﬁts the end of pregnancy
and lactation period of sows and improves the survival and
growth of their offspring during suckling and the ﬂat-deck
period [76].
Escherichia coli
Nissle 1917 (EcN)
Adult patients with inﬂammatory bowel disease: a systematic review [77]
Premature infants: signiﬁcantly stimulates speciﬁc humoral and cellular
responses and simultaneously induces non-speciﬁc natural immunity [78]
Children, infants and toddlers: exerts a strong immunomodulatory
effect, stops acute diarrhoea [79]
Human patients: strain frequently used for the treatment of gastrointestinal
complaints and is well tolerated [80]; signiﬁcant improvement of irritable
bowel syndrome-related constipation [81]; overview of the mechanisms
of action and clinical studies related to Mutaﬂor (EcN) [82]
Pigs: prevents acute secretory diarrhoea in pigs infected with
enterotoxigenic E. coli Abbotstown [83].
Piglets: EcN colonizes the intestine and persists in
conventionally reared piglets for at least 4 weeks upon oral
administration [84]
Swine: partial establishment of the strain in swine herds [85];
EcN is partially established in swine herds in Germany with
individual variability [85]
Adult healthy female pigsa: EcN administration not sufﬁcient for
stable colonization of porcine gut but induced signiﬁcant
changes in the enterobacterial microbiota [86]
Calf: clear beneﬁcial effect on the prophylaxis and treatment of
neonatal calf diarrhoea [87]
Lactobacillus
rhamnosus GG
LGG, Geﬁlus and Geﬁlac are trademarks of Valio Ltd. Together with
other branded products containing the same organisms; they are sold in
35 countries around the world (http://ammattilaiset.valio.ﬁ/portal/page/
portal/valiocom)
Prenatal: prenatal administration failed to modulate diversity of early infant
gut microbiota despite promoting a beneﬁcial biﬁdobacteria proﬁle [88]
Fetal status: maternal probiotic supplementation signiﬁcantly modulated the
expression of Toll-like receptor-related genes both in the placenta and in
the fetal gut. Microbial contact in utero is associated with changes in fetal
intestinal innate immune gene expression proﬁle [89]
Extremely low-birth-weight infants (ELBW): improves growth velocity in
ELBW infants, but no improvement in the % of infants with growth delay at
34 weeks postmenstrual age, no adverse events [90]
Infants from 0 to 6 months: children grew better [59]
Indian children with acute watery diarrhoea (AWD): effective to decrease the
frequency and duration of diarrhoea and reduction in hospital stay of AWD
patients [91]
Piglets: does not prevent or reduce the detrimental effect of
the E. coli F4 infection on the growth performance and health
status of weaned piglet [92]; effective in ameliorating
diarrhoea in post-weaning piglets induced by E. coli K88,
possibly via modulation of intestinal microﬂora, enhancement
of intestinal antibody defence, and regulation of production of
systemic inﬂammatory cytokines [93]
Horses and foals: absence of negative side effects [94]
Rainbow trout: enhancement of immune parameters [95]
Nile tilapia: important regulator of gut associated immune
systems [96]
Fish: suppression of ﬁsh pathogen growth [97]
Dogs: reduction of carriage of Clostridium perfringens [98];
absence of negative side effects and colonization at
1011 CFU/g [94]; unsuccessful to treat tylosin-responsive
diarrhoea [99]
Chickens: binds to aﬂatoxin AFB1 in vivo [100]
Calves: absence of negative side effects (as no D-lactate is
produced), survive intestinal transit in young calf [101]
Lactobacillus reuteri
MM53 = ATCC 55730
Children: abundant colonization of the gastrointestinal tract of infants from birth
up to 1 year of age [102]; reduction of the number of febrile episodes and
episodes of gastrointestinal infection, doctors’ visits and antibiotic use in
children [103]
Adults: signiﬁcantly stimulates immune system in the mucosa by increasing
the number of B lymphocytes in the duodenum and the number of T
lymphocytes in the ileum [104]; reduce gastrointestinal illness and infections and
the incidence and the severity of diarrhoea of different origins [105]
Hospitalized adults: decreases antibiotic-associated diarrhoea and safely tolerated
when administered twice daily for 4 weeks [106]
Weaning pigs: produces the same body weight gain as
sub-therapeutic levels of antibiotic [107]; daily ﬂuctuation in
speciﬁc bands of L. reuteri MM53 revealing an antagonistic
relationship between MM53 and another indigenous
Lactobacillus assemblage [108]
Chick infection model: antimicrobial activity and
immunomodulation in vitro, which were conﬁrmed in vivo by
the use of animal models [109]
Lactobacillus casei
Shirota
Dairy fermented milk helping to maintain a healthy balance of the intestinal ﬂora
and good for digestion (http://www.yakult.com.my/html/faqs.html)
Smokers: higher increase in cytotoxic activity and CD16+ cell numbers in
comparison to the placebo intake group [110]
Patients and cancer: review suggests that this speciﬁc strain may help the
reinforcement of defence system against cancer by modulating innate
immune functions [111]
Pigs: acts on gastrointestinal tract transit, stimulate colonic
fermentation and indigenous Lactobacillus [112–114]
Rabbit: protects against Shiga toxin-producing E. coli
O157:H7 [115]
Fish: sensitive to ﬁsh bile [97]
aSmall adult pigs were used as experimental omnivore models to study human gastrointestinal functions.
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[60,61]. In France, only appropriate epidemiological surveys,
such as the current French national cohort study Elfe [62],
reinforced by the current French national study Epifane [63]
could provide answers to this crucial question of the origins
of obesity. Meanwhile, promotion of ‘pharmacovigilance’
regarding probiotics applied for human use, especially by at-
risk populations as proposed by Bernardeau and Vernoux [4],
is highly recommended and should be investigated by scientists
as well as industrialists.
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